Response to immune checkpoint inhibitor combination therapy in metastatic RET-mutated lung cancer from real-world retrospective data.
Journal Information
Full Title: BMC Cancer
Abbreviation: BMC Cancer
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Declarations Ethics approval and consent to participateThe Ethics Committee of the First Affiliated Hospital of Zhengzhou University granted approval for this study and waived the requirement for informed consent due to its retrospective design. Consent for publicationNot applicable. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."
Funding Disclosure
Evidence found in paper:
"Funding The present study was funded by the Joint Construction Project of Henan Province and Ministry, grant number LHGJ20190013."
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025